title: [New therapeutic options for dry eye].
authors: E M
authors: EM
authors: Messmer
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003315:Cornea / Q000187:drug effects*; D004195:Disease Models, Animal; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000627:therapeutic use*; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000187:drug effects*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000737:chemistry*; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D011122:Polyphosphates / Q000008:administration & dosage*; D015363:Quinolones / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014500:Uracil Nucleotides / Q000008:administration & dosage*; D055675:Viscosupplements / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D000897:Anti-Ulcer Agents; D006877:Hydroxamic Acids; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D016169:Lymphocyte Function-Associated Antigen-1; D061965:Matrix Metalloproteinase Inhibitors; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D015363:Quinolones; D013449:Sulfonamides; D014500:Uracil Nucleotides; D055675:Viscosupplements; D006820:Hyaluronic Acid; D020780:Matrix Metalloproteinase 9; D000409:Alanine